AB 1060: Cancer clinical trials.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2015-09-14
Existing law establishes the scope and function of the California Health and Human Services Agency, which includes departments charged with administering laws pertaining to public health and social services, among other things. Existing law also establishes the Inclusion of Women and Minorities in Clinical Research Act, which is designed to promote the inclusion of women and minority groups in clinical research, including clinical trials.
This bill, until January 1, 2022, would establish the Cancer Clinical Trials Foundation in the Health and Human Services Agency, to be governed by a board of trustees. Members of the board would be appointed as specified. The bill would also create the Cancer Clinical Trials Fund, to be used to administer a grant program. The bill would limit the amount the agency may spend to establish the foundation to $300,000 of appropriated funds, to be repaid by January 1, 2021, but would otherwise prohibit General Fund moneys from being used for the foundation. The bill would authorize the board to solicit and receive money, as specified, and would authorize the agency to apply for federal funds for this purpose. The bill would require the board, upon contribution of at least $500,000 to the fund, to establish the Cancer Clinical Trials Grant Program, in order to increase patient access to cancer clinical trials in specified populations. The bill would require that grant money be used for designated purposes, and would also require grant recipients to report to the board. The bill would require the board to report to the Legislature, as specified. This bill would make related findings.
Existing law establishes the scope and function of the California Health and Human Services Agency, which includes departments charged with administering laws pertaining to public health and social services, among other things. Existing law also establishes the Inclusion of Women and Minorities in Clinical Research Act, which is designed to promote the inclusion of women and minority groups in clinical research, including clinical trials.
This bill bill, until January 1, 2022, would create establish the Cancer Clinical Trials Foundation in the Health and Human Services Agency, to be governed by a board of trustees. Members of the board would be appointed as specified. The bill would also create the Cancer Clinical Trials Fund, and would continuously appropriate this fund to the board, thereby making an appropriation. to be used to administer a grant program. The bill would limit the amount the agency may spend to establish the foundation to $300,000 of appropriated funds, to be repaid by January 1, 2021, but would otherwise prohibit General Fund moneys from being used for the foundation. The bill would authorize the board to solicit and receive money, as specified. specified, and would authorize the agency to apply for federal funds for this purpose. The bill would require the board, upon contribution of an unspecified amount of money at least $500,000 to the fund, to establish the Cancer Clinical Trials Grant Program, in order to increase patient access to cancer clinical trials in specified populations. The bill would require that grant money be used for designated purposes, and would also require grant recipients to report to the board. The bill would require the board to report to the Legislature, as specified. This bill would make related findings.
Existing law establishes the scope and function of the California Health and Human Services Agency, which includes departments charged with administering laws pertaining to public health and social services, among other things. Existing law also establishes the Inclusion of Women and Minorities in Clinical Research Act, which is designed to promote the inclusion of women and minority groups in clinical research, including clinical trials.
This bill would create the Cancer Clinical Trials Foundation in the Health and Human Services Agency, to be governed by a board of trustees. Members of the board would be appointed as specified. The bill would also create the Cancer Clinical Trials Fund, and would continuously appropriate this fund to the board, thereby making an appropriation. The bill would authorize the board to solicit and receive money, as specified. The bill would require the board, upon contribution of an unspecified amount of money to the fund, to establish the Cancer Clinical Trials Grant Program, in order to increase patient access to cancer clinical trials in specified populations. The bill would require that grant money be used for designated purposes, and would also require grant recipients to report to the board. The bill would require the board to report to the Legislature, as specified. This bill would make related findings.
Existing law establishes the scope and function of the California Health and Human Services Agency, which includes departments charged with administering laws pertaining to public health and social services, among other things. Existing law also establishes the Inclusion of Women and Minorities in Clinical Research Act, which is designed to promote the inclusion of women and minority groups in clinical research, including clinical trials.
This bill would create the Cancer Clinical Trials Foundation in the Health and Human Services Agency, to be governed by a board of trustees. Members of the board would be appointed as specified. The bill would also create the Cancer Clinical Trials Fund, and would continuously appropriate this fund to the board, thereby making an appropriation. The bill would authorize the board to solicit and receive money, as specified. The bill would require the board, upon contribution of an unspecified amount of money to the fund, to establish the Cancer Clinical Trials Grant Program, in order to increase patient access to cancer clinical trials in specified populations. The bill would require that grant money be used for designated purposes, and would also require grant recipients to report to the board. The bill would require the board to report to the Legislature, as specified. This bill would make related findings.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law authorizes a board to suspend or revoke a license on the ground that the licensee has been convicted of a crime, if the crime is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. Existing law requires the board, upon suspension or revocation of a license, to provide the ex-licensee with certain information pertaining to rehabilitation, reinstatement, or reduction of penalty, as specified.
This bill would require the board to provide that information through first-class mail and by email if the board has an email address on file for the ex-licensee.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law authorizes a board to suspend or revoke a license on the ground that the licensee has been convicted of a crime, if the crime is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. Existing law requires the board, upon suspension or revocation of a license, to provide the ex-licensee with certain information pertaining to rehabilitation, reinstatement, or reduction of penalty, as specified.
This bill would authorize require the board to provide that information through first-class mail and by electronic means. email if the board has an email address on file for the ex-licensee.
Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law authorizes a board to suspend or revoke a license on the ground that the licensee has been convicted of a crime, if the crime is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. Existing law requires the board, upon suspension or revocation of a license, to provide the ex-licensee with certain information pertaining to rehabilitation, reinstatement, or reduction of penalty, as specified.
This bill would authorize the board to provide that information through first-class mail and by electronic means.
The Legislature finds and declares the following:
(a)Almost 50 percent of clinical trial studies are not finished in time due to low patient participation, recruitment and navigation difficulties, and other barriers for patients. Due to economic and socioeconomic circumstances and lack of patient knowledge, clinical oncology trial participation and retention are both very low as they relate to eligible participants.
(b)Overall, only 3 percent of eligible cancer patients participate in clinical trials, and of those only 5 percent of trial participants are from racial or ethnic minority communities.
(c)One barrier that prevents patients from participating in federal Food and Drug Administration clinical trials is finances. Patients of low to moderate income are often unable to bear the burden of the ancillary costs of participating, such as airfare, lodging, rental cars, and fuel.
(d)The American Medical Association conducted a study on cancer trial participation. The study found that from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1 percent were Hispanic, 9.2 percent were Black, and 1.9 percent were Asian or Pacific Islanders, while 85.6 percent were White. This lack of diversity is of concern because of its impact on researchers ability to evaluate the effect of new treatments on different populations. It also speaks to a lack of access to potentially lifesaving trials for a large portion of the population.
(e)It is the intent of the Legislature to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
SEC. 2.Chapter 2 (commencing with Section 101990) is added to Part 6 of Division 101 of the Health and Safety Code, to read:2.Cancer Clinical Trials101990.(a)Board means the Board of Trustees of the Cancer Clinical Trials Foundation.
(b)Foundation means the Cancer Clinical Trials Foundation.
(c)Fund means the Cancer Clinical Trials Fund.
101991.(a)The agency shall establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, that shall be governed by a board consisting of a total of five members. Three members shall be appointed by the Governor. Of these members, one shall be from a public cancer research institution, and one shall be from a private cancer research institution. One member shall be appointed by the Speaker of the Assembly. One member shall be appointed by the President pro Tempore of the Senate.
(b)All persons appointed to the board shall have an interest in increasing access to cancer clinical trials and the ability and desire to solicit funds for the purpose of increasing access to clinical trials as provided in this chapter.
(c)The Governor shall appoint the president of the board from among those members appointed by the Governor, the Speaker of the Assembly, and the President pro Tempore of the Senate.
(d)The foundation, or an authorized representative thereof, shall apply for tax exempt status under Section 501(c)(3) of the Internal Revenue Code.
(e)Members of the board shall serve without compensation but shall be reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
(f)The foundation shall be subject to the Nonprofit Public Benefit Corporation Law (Part 2 (commencing with Section 5110) of Division 2 of Title 2 of the Corporations Code).
(g)The California Health and Human Services Agency shall determine which department in the agency shall administer the foundation.
101992.(a)Of the members of the board first appointed by the Governor pursuant to Section 101991, one member shall be appointed to serve a two-year term, one member shall be appointed to serve a three-year term, and one member shall be appointed to serve a four-year term.
(b)Of the members of the board first appointed by the Speaker of the Assembly and the President pro Tempore of the Senate pursuant to Section 101991, each member shall be appointed to serve a four-year term.
(c)Upon the expiration of the initial appointments for the board, each member shall be appointed to serve a four-year term.
101993.(a)There is hereby created in the State Treasury the Cancer Clinical Trials Fund. Moneys in the fund shall be used for the administration and support of the program created pursuant to this chapter upon appropriation of the Legislature.
(b)The Cancer Clinical Trials Foundation may solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
(c)The agency may apply for federal funds for the foundation.
(d)The board shall use no more than 20 percent of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
101993.5.(a)The agency may not spend more than three hundred thousand dollars ($300,000) of moneys appropriated to the agency to establish the foundation.
(b)Any money used to establish the foundation shall be paid back to the agency on or before January 1, 2021, from moneys donated to the Cancer Clinical Trials Fund.
(c)After the initial investment authorized by subdivision (a), no General Fund moneys shall be used to operate the foundation.
101994.(a)Upon contribution of at least five hundred thousand dollars ($500,000) to the foundation, the board shall establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities. The board shall determine the criteria to award grants, and may award grants to either or both of the following:
(1)Public and private research institutions and hospitals that conduct cancer clinical trials approved by the federal Food and Drug Administration.
(2)Nonprofit organizations described in Section 501(c)(3) of the Internal Revenue Code of 1954 that are exempt from income tax under Section 501(a) of that code and that specialize in direct patient support for improved clinical trial enrollment and retention.
(b)Grants awarded pursuant to subdivision (a) shall be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
(1)Patient navigator services or programs.
(2)Education and community outreach.
(3)Patient-friendly technical tools to assist patients in identifying available clinical trials.
(4)Translation and interpretation services of clinical trial information.
(5)Counseling services for clinical trial participants.
(6)Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management.
(7)Payment of ancillary costs for patients and caregivers, including, but not limited to:
(A)Airfare during the clinical trial.
(B)Lodging during the clinical trial.
(C)Rental cars during the clinical trial.
(D)Fuel during the clinical trial.
(E)Local transportation via bus, train, or other public transportation during the clinical trial.
(F)Meals during the clinical trial.
(G)Child care costs during the clinical trial.
(c)If the foundation does not receive five hundred thousand dollars ($500,000) or more by January 1, 2021, moneys remaining after the repayment required pursuant to subdivision (b) of Section 101993.5 shall be returned to the donors on a pro rata basis.
(d)If the grant program is established pursuant to this section, all moneys in the fund shall be awarded by grant prior to the repeal of this chapter.
101995.(a)Grant recipients shall report to the board to ensure the appropriate use of funds within one year of receiving a grant.
(b)(1)The board shall report to the Legislature to ensure the appropriate use of the funds. The report shall include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program. This report shall be submitted by January 1, 2020.
(2)The requirement for submitting a report imposed under paragraph (1) is inoperative on January, 1, 2024, pursuant to Section 10231.5 of the Government Code.
101996.This chapter shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
The Legislature finds and declares the following:
(a)Almost 50 percent of clinical trial studies are not finished in time due to low patient participation, recruitment and navigation difficulties, and other barriers for patients. Due to economic and socioeconomic circumstances and lack of patient knowledge, clinical oncology trial participation and retention are both very low as they relate to eligible participants.
(b)Overall, only 3 percent of eligible cancer patients participate in clinical trials, and of those only 5 percent of trial participants are from racial or ethnic minority communities.
(c)One barrier that prevents patients from participating in federal Food and Drug Administration clinical trials is finances. Patients of low to moderate income are often unable to bear the burden of the ancillary costs of participating, such as airfare, lodging, rental cars, and fuel.
(d)The American Medical Association conducted a study on cancer trial participation. The study found that from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1 percent were Hispanic, 9.2 percent were Black, and 1.9 percent were Asian or Pacific Islanders, while 85.6 percent were White. This lack of diversity is of concern because of its impact on researchers ability to evaluate the effect of new treatments on different populations. It also speaks to a lack of access to potentially lifesaving trials for a large portion of the population.
(e)It is the intent of the Legislature to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
SEC. 2.Chapter 2 (commencing with Section 101990) is added to Part 6 of Division 101 of the Health and Safety Code, to read:2.Cancer Clinical Trials101990.(a)Board means the Board of Trustees of the Cancer Clinical Trials Foundation.
(b)Foundation means the Cancer Clinical Trials Foundation.
(c)Fund means the Cancer Clinical Trials Fund.
101991.(a)The agency shall establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, that shall be governed by a board consisting of a total of five members. Three members shall be appointed by the Governor. Of these members, one shall be from a public cancer research institution, and one shall be from a private cancer research institution. One member shall be appointed by the Speaker of the Assembly. One member shall be appointed by the President pro Tempore of the Senate.
(b)All persons appointed to the board shall have an interest in increasing access to cancer clinical trials and the ability and desire to solicit funds for the purpose of increasing access to clinical trials as provided in this chapter.
(b)
(c)The Governor shall appoint the president of the board from among those members appointed by the Governor, the Speaker of the Assembly, and the President pro Tempore of the Senate.
(c)
(d)The foundation, or an authorized representative thereof, shall apply for tax exempt status under Section 501(c)(3) of the Internal Revenue Code.
(d)
(e)Members of the board shall serve without compensation but shall be reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
(e)
(f)The foundation shall be subject to the Nonprofit Public Benefit Corporation Law (Part 2 (commencing with Section 5110) of Division 2 of Title 2 of the Corporations Code).
(f)
(g)The California Health and Human Services Agency shall determine which department in the agency shall administer the foundation.
101992.(a)Of the members of the board first appointed by the Governor pursuant to Section 101991, one member shall be appointed to serve a two-year term, one member shall be appointed to serve a three-year term, and one member shall be appointed to serve a four-year term.
(b)Of the members of the board first appointed by the Speaker of the Assembly and the President pro Tempore of the Senate pursuant to Section 101991, each member shall be appointed to serve a four-year term.
(c)Upon the expiration of the initial appointments for the board, each member shall be appointed to serve a four-year term.
101993.(a)There is hereby created in the State Treasury the Cancer Clinical Trials Fund. Notwithstanding Section 13340 of the Government Code, all money Moneys in the fund is continuously appropriated to the board without regard to fiscal years, shall be used for the administration and support of the program created pursuant to this chapter. chapter upon appropriation of the Legislature.
(b)The Cancer Clinical Trials Foundation may solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
(c)The agency may apply for federal funds for the foundation.
(c)
(d)The board shall use no more than 20 percent of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
101993.5.(a)The agency may not spend more than three hundred thousand dollars ($300,000) of moneys appropriated to the agency to establish the foundation.
(b)Any money used to establish the foundation shall be paid back to the agency on or before January 1, 2021, from moneys donated to the Cancer Clinical Trials Fund.
(c)After the initial investment authorized by subdivision (a), no General Fund moneys shall be used to operate the foundation.
101994.(a)Upon contribution of an unspecified amount of moneys at least five hundred thousand dollars ($500,000) to the foundation, the board shall establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities. The board shall determine the criteria to award grants, and may award grants to either or both of the following:
(1)Public and private research institutions and hospitals that conduct cancer clinical trials approved by the federal Food and Drug Administration.
(2)Nonprofit organizations described in Section 501(c)(3) of the Internal Revenue Code of 1954 that are exempt from income tax under Section 501(a) of that code and that specialize in direct patient support for improved clinical trial enrollment and retention.
(b)Grants awarded pursuant to subdivision (a) shall be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
(1)Patient navigator services or programs.
(2)Education and community outreach.
(3)Patient-friendly technical tools to assist patients in identifying available clinical trials.
(4)Translation and interpretation services of clinical trial information.
(5)Counseling services for clinical trial participants.
(6)Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management.
(7)Payment of ancillary costs for patients and caregivers, including, but not limited to:
(A)Airfare during the clinical trial.
(B)Lodging during the clinical trial.
(C)Rental cars during the clinical trial.
(D)Fuel during the clinical trial.
(E)Local transportation via bus, train, or other public transportation during the clinical trial.
(F)Meals during the clinical trial.
(G)Child care costs during the clinical trial.
(c)If the foundation does not receive five hundred thousand dollars ($500,000) or more by January 1, 2021, moneys remaining after the repayment required pursuant to subdivision (b) of Section 101993.5 shall be returned to the donors on a pro rata basis.
(d)If the grant program is established pursuant to this section, all moneys in the fund shall be awarded by grant prior to the repeal of this chapter.
101995.(a)Grant recipients shall report to the board to ensure the appropriate use of funds within one year of receiving a grant.
(b)(1)The board shall report to the Legislature to ensure the appropriate use of the funds. The report shall include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program. This report shall be submitted by January 1, 2020.
(2)The requirement for submitting a report imposed under paragraph (1) is inoperative on January, 1, 2024, pursuant to Section 10231.5 of the Government Code.
101996.This chapter shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
The Legislature finds and declares the following:
(a)Almost 50 percent of clinical trial studies are not finished in time due to low patient participation, recruitment and navigation difficulties, and other barriers for patients. Due to economic and socioeconomic circumstances and lack of patient knowledge, clinical oncology trial participation and retention are both very low as they relate to eligible participants.
(b)Overall, only 3 percent of eligible cancer patients participate in clinical trials, and of those only 5 percent of trial participants are from racial or ethnic minority communities.
(c)One barrier that prevents patients from participating in federal Food and Drug Administration clinical trials is finances. Patients of low to moderate income are often unable to bear the burden of the ancillary costs of participating, such as airfare, lodging, rental cars, and fuel.
(d)The American Medical Association conducted a study on cancer trial participation. The study found that from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1 percent were Hispanic, 9.2 percent were Black, and 1.9 percent were Asian or Pacific Islanders, while 85.6 percent were White. This lack of diversity is alarming of concern because of its impact on researchers ability to evaluate the effect of new treatments on different populations. It also speaks to a lack of access to potentially lifesaving trials for a large portion of the population.
(e)It is the intent of the Legislature to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
SEC. 2.Chapter 2 (commencing with Section 101990) is added to Part 6 of Division 101 of the Health and Safety Code, to read:2.Cancer Clinical Trials101990.(a)Board means the Board of Trustees of the Cancer Clinical Trials Foundation.
(b)Foundation means the Cancer Clinical Trials Foundation.
(c)Fund means the Cancer Clinical Trials Fund.
101991.(a)The agency shall establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, that shall be governed by a board consisting of a total of five members. Three members shall be appointed by the Governor. Of these members, one shall be from a public cancer research institution, and one shall be from a private cancer research institution. One member shall be appointed by the Speaker of the Assembly. One member shall be appointed by the President pro Tempore of the Senate.
(b)The Governor shall appoint the president of the board from among those members appointed by the Governor, the Speaker of the Assembly, and the President pro Tempore of the Senate.
(c)The foundation, or an authorized representative thereof, shall apply for tax exempt status under Section 501(c)(3) of the Internal Revenue Code.
(c)
(d)Members of the board shall serve without compensation but shall be reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
(d)
(e)The foundation shall be subject to the Nonprofit Public Benefit Corporation Law (Part 2 (commencing with Section 5110) of Division 2 of Title 2 of the Corporations Code), except that if there is a conflict with this chapter and the Nonprofit Public Benefit Corporation Law, this chapter shall prevail. Code).
(e)
(f)The California Health and Human Services Agency shall determine which department in the agency shall administer the foundation.
101992.(a)Of the members of the board first appointed by the Governor pursuant to Section 101991, one member shall be appointed to serve a two-year term, one member shall be appointed to serve a three-year term, and one member shall be appointed to serve a four-year term.
(b)Of the members of the board first appointed by the Speaker of the Assembly and the President pro Tempore of the Senate pursuant to Section 101991, each member shall be appointed to serve a four-year term.
(c)Upon the expiration of the initial appointments for the board, each member shall be appointed to serve a four-year term.
101993.(a)There is hereby created the Cancer Clinical Trials Fund. Notwithstanding Section 13340 of the Government Code, all money in the fund is continuously appropriated to the board without regard to fiscal years, for the administration and support of the program created pursuant to this chapter.
(b)The Cancer Clinical Trials Foundation may solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
(c)The board shall use no more than 20 percent of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
101994.(a)Upon contribution of an unspecified amount of moneys to the foundation, the board shall establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities. The board shall determine the criteria to award grants, and may award grants to either or both of the following:
(1)Public and private research institutions and hospitals that conduct cancer clinical trials approved by the federal Food and Drug Administration.
(2)Nonprofit organizations described in Section 501(c)(3) of the Internal Revenue Code of 1954 that are exempt from income tax under Section 501(a) of that code and that specialize in direct patient support for improved clinical trial enrollment and retention.
(b)Grants awarded pursuant to subdivision (a) shall be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
(1)Patient navigator services or programs.
(2)Education and community outreach.
(3)Patient-friendly technical tools to assist patients in identifying available clinical trials.
(4)Translation and interpretation services of clinical trial information.
(5)Counseling services for clinical trial participants.
(6)Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management.
(7)Payment of ancillary costs for patients and caregivers, including, but not limited to:
(A)Airfare during the clinical trial.
(B)Lodging during the clinical trial.
(C)Rental cars during the clinical trial.
(D)Fuel during the clinical trial.
(E)Local transportation via bus, train, or other public transportation during the clinical trial.
(F)Meals during the clinical trial.
(G)Child care costs during the clinical trial.
101995.(a)Grant recipients shall report to the board to ensure the appropriate use of funds within one year of receiving a grant.
(b)(1)The board shall report to the Legislature to ensure the appropriate use of the funds. The report shall include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program. This report shall be submitted by January 1, 2020.
(2)The requirement for submitting a report imposed under paragraph (1) is inoperative on January, 1, 2024, pursuant to Section 10231.5 of the Government Code.
The Legislature finds and declares the following:
(a)Almost 50 percent of clinical trial studies are not finished in time due to low patient participation, recruitment and navigation difficulties, and other barriers for patients. Due to economic and socioeconomic circumstances and lack of patient knowledge, clinical oncology trial participation and retention are both very low as they relate to eligible participants.
(b)Overall, only 3 percent of eligible cancer patients participate in clinical trials, and of those only 5 percent of trial participants are from racial or ethnic minority communities.
(c)One barrier that prevents patients from participating in federal Food and Drug Administration clinical trials is finances. Patients of low to moderate income are often unable to bear the burden of the ancillary costs of participating, such as airfare, lodging, rental cars, and fuel.
(d)The American Medical Association conducted a study on cancer trial participation. The study found that from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1 percent were Hispanic, 9.2 percent were Black, and 1.9 percent were Asian or Pacific Islanders, while 85.6 percent were White. This lack of diversity is alarming because of its impact on researchers ability to evaluate the effect of new treatments on different populations. It also speaks to a lack of access to potentially lifesaving trials for a large portion of the population.
(e)It is the intent of the Legislature to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
SEC. 2.Chapter 2 (commencing with Section 101990) is added to Part 6 of Division 101 of the Health and Safety Code, to read:2.Cancer Clinical Trials101990.(a)Board means the Board of Trustees of the Cancer Clinical Trials Foundation.
(b)Foundation means the Cancer Clinical Trials Foundation.
(c)Fund means the Cancer Clinical Trials Fund.
101991.(a)The agency shall establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, that shall be governed by a board consisting of a total of five members. Three members shall be appointed by the Governor. Of these members, one shall be from a public cancer research institution, and one shall be from a private cancer research institution. One member shall be appointed by the Speaker of the Assembly. One member shall be appointed by the President pro Tempore of the Senate.
(b)The Governor shall appoint the president of the board from among those members appointed by the Governor, the Speaker of the Assembly, and the President pro Tempore of the Senate.
(c)Members of the board shall serve without compensation but shall be reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
(d)The foundation shall be subject to the Nonprofit Public Benefit Corporation Law (Part 2 (commencing with Section 5110) of Division 2 of Title 2 of the Corporations Code), except that if there is a conflict with this chapter and the Nonprofit Public Benefit Corporation Law, this chapter shall prevail.
(e)The California Health and Human Services Agency shall determine which department in the agency shall administer the foundation.
101992.(a)Of the members of the board first appointed by the Governor pursuant to Section 101991, one member shall be appointed to serve a two-year term, one member shall be appointed to serve a three-year term, and one member shall be appointed to serve a four-year term.
(b)Of the members of the board first appointed by the Speaker of the Assembly and the President pro Tempore of the Senate pursuant to Section 101991, each member shall be appointed to serve a four-year term.
(c)Upon the expiration of the initial appointments for the board, each member shall be appointed to serve a four-year term.
101993.(a)There is hereby created the Cancer Clinical Trials Fund. Notwithstanding Section 13340 of the Government Code, all money in the fund is continuously appropriated to the board without regard to fiscal years, for the administration and support of the program created pursuant to this chapter.
(b)The Cancer Clinical Trials Foundation may solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
(c)The board shall use no more than 20 percent of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
101994.(a)Upon contribution of an unspecified amount of moneys to the foundation, the board shall establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities. The board shall determine the criteria to award grants, and may award grants to either or both of the following:
(1)Public and private research institutions and hospitals that conduct cancer clinical trials approved by the federal Food and Drug Administration.
(2)Nonprofit organizations described in Section 501(c)(3) of the Internal Revenue Code of 1954 that are exempt from income tax under Section 501(a) of that code and that specialize in direct patient support for improved clinical trial enrollment and retention.
(b)Grants awarded pursuant to subdivision (a) shall be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
(1)Patient navigator services or programs.
(2)Education and community outreach.
(3)Patient-friendly technical tools to assist patients in identifying available clinical trials.
(4)Translation and interpretation services of clinical trial information.
(5)Counseling services for clinical trial participants.
(6)Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management.
(7)Payment of ancillary costs for patients and caregivers, including, but not limited to:
(A)Airfare during the clinical trial.
(B)Lodging during the clinical trial.
(C)Rental cars during the clinical trial.
(D)Fuel during the clinical trial.
(E)Local transportation via bus, train, or other public transportation during the clinical trial.
(F)Meals during the clinical trial.
(G)Child care costs during the clinical trial.
101995.(a)Grant recipients shall report to the board to ensure the appropriate use of funds within one year of receiving a grant.
(b)(1)The board shall report to the Legislature to ensure the appropriate use of the funds. The report shall include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program. This report shall be submitted by January 1, 2020.
(2)The requirement for submitting a report imposed under paragraph (1) is inoperative on January, 1, 2024, pursuant to Section 10231.5 of the Government Code.
SECTION 1.Section 491 of the Business and Professions Code is amended to read:491.(a)Upon suspension or revocation of a license by a board on one or more of the grounds specified in Section 490, the board shall:
(1)Send a copy of the provisions of Section 11522 of the Government Code to the ex-licensee.
(2)Send a copy of the criteria relating to rehabilitation formulated under Section 482 to the ex-licensee.
(b)Subdivision (a) shall be satisfied through first-class mail and by email if the board has an email address on file for the ex-licensee.
(a)Upon suspension or revocation of a license by a board on one or more of the grounds specified in Section 490, the board shall:
(1)Send a copy of the provisions of Section 11522 of the Government Code to the ex-licensee.
(2)Send a copy of the criteria relating to rehabilitation formulated under Section 482 to the ex-licensee.
(b)Subdivision (a) may shall be satisfied through first-class mail and by electronic means. email if the board has an email address on file for the ex-licensee.
(a)Upon suspension or revocation of a license by a board on one or more of the grounds specified in Section 490, the board shall:
(a)
(1)Send a copy of the provisions of Section 11522 of the Government Code to the ex-licensee.
(b)
(2)Send a copy of the criteria relating to rehabilitation formulated under Section 482 to the ex-licensee.
(b)Subdivision (a) may be satisfied through first-class mail and by electronic means.
|
Date
|
Status
|
|---|---|
| Jan 15, 2016 | Consideration of Governor's veto stricken from file. |
| Oct 5, 2015 | Vetoed by Governor. |
| Sep 18, 2015 | Enrolled and presented to the Governor at 4 p.m. |
| Sep 10, 2015 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 72. Noes 6. Page 3050.). |
| Sep 10, 2015 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 72. Noes 6.). |
| Sep 10, 2015 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Sep 9, 2015 | Joint Rule 62(a), file notice suspended. (Page 2989.) |
| Sep 9, 2015 | From committee: That the Senate amendments be concurred in. (Ayes 17. Noes 1.) (September 9). |
| Sep 9, 2015 | Joint Rule 62(a), file notice suspended. |
| Sep 4, 2015 | Re-referred to Com. on HEALTH. pursuant to Assembly Rule 77.2. |
| Sep 3, 2015 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0. Page 2481.). |
| Sep 3, 2015 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 5 pursuant to Assembly Rule 77. |
| Sep 3, 2015 | Read third time. Passed. Ordered to the Assembly. |
| Aug 31, 2015 | Read second time and amended. Ordered to third reading. |
| Aug 27, 2015 | From committee: Amend, and do pass as amended. (Ayes 7. Noes 0.) (August 27). |
| Aug 17, 2015 | In committee: Referred to APPR. suspense file. |
| Jul 16, 2015 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 16, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (July 15). |
| Jun 19, 2015 | Re-referred to Com. on HEALTH. |
| Jun 18, 2015 | Re-referred to Com. on RLS. |
| Jun 18, 2015 | Withdrawn from committee. |
| Jun 17, 2015 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| May 21, 2015 | Referred to Com. on B., P. & E.D. |
| May 7, 2015 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 7, 2015 | Read third time. Passed. Ordered to the Senate. (Ayes 77. Noes 0. Page 1349.) |
| May 7, 2015 | Read third time. Passed. Ordered to the Senate. |
| Apr 30, 2015 | Read second time. Ordered to Consent Calendar. |
| Apr 29, 2015 | From committee: Do pass. To Consent Calendar. (Ayes 17. Noes 0.) (April 29). |
| Apr 14, 2015 | From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 14. Noes 0.) (April 14). Re-referred to Com. on APPR. |
| Apr 6, 2015 | Re-referred to Com. on B. & P. |
| Mar 26, 2015 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Mar 19, 2015 | Referred to Com. on B. & P. |
| Feb 27, 2015 | From printer. May be heard in committee March 29. |
| Feb 26, 2015 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 10, 2015 | AB 1060 BONILLA Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 9, 2015 | With recommendation: That Senate amendments be concurred in. | Assembly Standing Committee on Health |
Passed |
|
| Sep 3, 2015 | Assembly 3rd Reading AB1060 Bonilla By Pan | Senate Floor |
Passed |
|
| Aug 27, 2015 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 17, 2015 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 15, 2015 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 7, 2015 | AB 1060 BONILLA Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 29, 2015 | Do pass. To Consent Calendar. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 14, 2015 | Do pass and be re-referred to the Committee on [Appropriations] with recommendation: To Consent Calendar | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
GOVERNOR'S VETO
AB 1060
(Bonilla)
As Enrolled September 14, 2015
2/3 vote
ASSEMBLY: |
|
(May 7, 2015) |
SENATE: |
39-0 |
(September 3, 2015) |
(vote not relevant)
COMMITTEE VOTE: |
17-1 |
(September 9, 2015) |
RECOMMENDATION: |
concur |
(HEALTH)
ASSEMBLY: |
72-6 |
(September 10, 2015) |
|
|
|
Original Committee Reference: B. & P.
SUMMARY: Requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to, and diverse participation in, cancer clinical trials.
The Senate amendments delete the previous Assembly-approved provisions of this bill and replace contents with this bill.
FISCAL EFFECT: According to the Senate Appropriations Committee, one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund). Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
COMMENTS: The author states that this bill would increase participation of underrepresented communities in United States (U.S.) Food and Drug Administration approved clinical trials by creating a privately funded state grant program to help patients pay for the ancillary cost associated with participation in these trials. Studies show that there is a disproportionately low number of patients from minority communities in clinical trials of new drugs and cancer therapies. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. Clinical trials do not pay these ancillary costs. The costs fall onto the clinical trial participant who may be unable to pay and therefore, unable to enroll in the trial. The author contends that this bill creates an opportunity for the state to leverage public-private partnerships to improve the health and wellbeing of its residents with limited state investment.
According to the Intercultural Cancer Center, only about 3% to 5% of the 10.1 million adults with cancer in the U.S. participate in cancer clinical trials. Clinical trials are a critical step in the discovery of new prevention, diagnostic, and treatment methods for cancer. Racial and ethnic minorities, older adults, rural residents, and individuals of low socioeconomic status are underrepresented among participants in cancer-related trials. Without adequate representation of these populations in clinical trials, researchers cannot learn about potential difference among groups and cannot ensure the generalization of results. In addition, participation in clinical trials increases access to state-of-the-art cancer care, a critical survival factor in many minority and underrepresent populations that suffer disproportionately from cancer.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3% to 5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. The National Cancer Institute is the largest sponsor of cancer clinical trials at 3,000 sites. Over 30,000 patients are enrolled in cancer clinical trials annually. A review of Food and Drug Administration approved drugs from 1995 to 1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities.
Barriers to Trial Participation. There are many different factors that have been attributed, in part, to the very low participation rate of all eligible patients in clinical trials, and the disproportionately low participation rate of minority populations. They include, among many other things:
Lack of awareness: A national survey of cancer patients found that 85% of respondents were unaware that participating in a clinical trial was a treatment option for them.
Language/Linguistic differences: Many U.S. clinical trials require English proficiency for potential participants, automatically excluding those who do not speak the language. Language factors also pose a serious barrier to provider-patient communication.
Practical obstacles: Transportation to and from a trial, particularly if it is located in a distant location, can be a barrier for many patients.
Public misconception: Among patients that are aware of clinical trials, a large percentage choose not to enroll, often due to a fear of getting a placebo in place of actual treatment, belief that standard treatment is better than what they would be offered in a clinical trial and fear of being a "guinea pig." In fact, placebos are rarely used in cancer treatment trials, and never in lieu of standard treatment.
Physician lack of awareness: Primary care physicians do not have sufficient information on available clinical trials, fail to refer patients to trials, and often leave the discussion of clinical research to the patient’s oncologist. Yet, many oncologists outside of the academic setting may also not be aware of trials or otherwise choose not to participate in or refer their eligible patients to clinical trials.
The University of Southern California writes in support that this bill will help improve patient access, especially for women and underrepresented minorities, to clinical trials by establishing a privately-funded state grant program. The current lack of diversity in clinical trial participants is alarming and negatively impact the ability of researchers to evaluate the effect of new treatments on different populations.
There is no known opposition to this bill.
This bill would direct the California Health and Human Services Agency to create a non-profit foundation to solicit donations to fund participation in cancer clinical trials."
"Numerous private organizations already perform this fundraising function. While I support eliminating barriers to take part in clinical trials, I am hesitant to place this new burden on the Health and Human Services Agency which is managing a huge expansion of our health care system.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN:0002461
AB 1060
Page 2
CONCURRENCE IN SENATE AMENDMENTS
AB 1060
(Bonilla)
As Amended August 31, 2015
Majority vote
ASSEMBLY: |
|
(May 7, 2015) |
SENATE: |
39-0 |
(September 3, 2015) |
(vote not relevant)
COMMITTEE VOTE: |
17-1 |
(September 9, 2015) |
RECOMMENDATION: |
concur |
(HEALTH)
Original Committee Reference: HEALTH
SUMMARY: Requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to, and diverse participation in, cancer clinical trials.
The Senate amendments delete the previous Assembly-approved provisions of this bill and replace contents with this bill.
FISCAL EFFECT: According to the Senate Appropriations Committee, one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund). Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
COMMENTS: The author states that this bill would increase participation of underrepresented communities in United States (U.S.) Food and Drug Administration approved clinical trials by creating a privately funded state grant program to help patients pay for the ancillary cost associated with participation in these trials. Studies show that there is a disproportionately low number of patients from minority communities in clinical trials of new drugs and cancer therapies. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. Clinical trials do not pay these ancillary costs. The costs fall onto the clinical trial participant who may be unable to pay and therefore, unable to enroll in the trial. The author contends that this bill creates an opportunity for the state to leverage public-private partnerships to improve the health and wellbeing of its residents with limited state investment.
According to the Intercultural Cancer Center, only about 3% to 5% of the 10.1 million adults with cancer in the U.S. participate in cancer clinical trials. Clinical trials are a critical step in the discovery of new prevention, diagnostic, and treatment methods for cancer. Racial and ethnic minorities, older adults, rural residents, and individuals of low socioeconomic status are underrepresented among participants in cancer-related trials. Without adequate representation of these populations in clinical trials, researchers cannot learn about potential difference among groups and cannot ensure the generalization of results. In addition, participation in clinical trials increases access to state-of-the-art cancer care, a critical survival factor in many minority and underrepresent populations that suffer disproportionately from cancer.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3% to 5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. The National Cancer Institute is the largest sponsor of cancer clinical trials at 3,000 sites. Over 30,000 patients are enrolled in cancer clinical trials annually. A review of Food and Drug Administration approved drugs from 1995 to 1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities.
Barriers to Trial Participation. There are many different factors that have been attributed, in part, to the very low participation rate of all eligible patients in clinical trials, and the disproportionately low participation rate of minority populations. They include, among many other things:
Lack of awareness: A national survey of cancer patients found that 85% of respondents were unaware that participating in a clinical trial was a treatment option for them.
Language/Linguistic differences: Many U.S. clinical trials require English proficiency for potential participants, automatically excluding those who do not speak the language. Language factors also pose a serious barrier to provider-patient communication.
Practical obstacles: Transportation to and from a trial, particularly if it is located in a distant location, can be a barrier for many patients.
Public misconception: Among patients that are aware of clinical trials, a large percentage choose not to enroll, often due to a fear of getting a placebo in place of actual treatment, belief that standard treatment is better than what they would be offered in a clinical trial and fear of being a "guinea pig." In fact, placebos are rarely used in cancer treatment trials, and never in lieu of standard treatment.
Physician lack of awareness: Primary care physicians do not have sufficient information on available clinical trials, fail to refer patients to trials, and often leave the discussion of clinical research to the patient’s oncologist. Yet, many oncologists outside of the academic setting may also not be aware of trials or otherwise choose not to participate in or refer their eligible patients to clinical trials.
The University of Southern California writes in support that this bill will help improve patient access, especially for women and underrepresented minorities, to clinical trials by establishing a privately-funded state grant program. The current lack of diversity in clinical trial participants is alarming and negatively impact the ability of researchers to evaluate the effect of new treatments on different populations.
There is no known opposition to this bill.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN: 0002341
AB 1060
Page 5
CONCURRENCE IN SENATE AMENDMENTS
AB 1060
(Bonilla)
As Amended August 31, 2015
Majority vote
ASSEMBLY: |
|
(May 7, 2015) |
SENATE: |
39-0 |
(September 3, 2015) |
(vote not relevant)
Original Committee Reference: B. & P.
SUMMARY: Requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
The Senate amendments delete the Assembly-approved contents of this bill and instead:
Require the California Health and Human Services Agency (CHHS) to establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, governed by a five member board, appointed by the Governor, the Speaker of the Assembly, and the Pro Tem of the Senate with a four year term.
Require the Governor to appoint the president of the board and requires members of the board to serve without compensation but reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
Subjects the foundation to the Nonprofit Public Benefit Corporation Law, as specified, except that if there is a conflict with this bill and the Nonprofit Public Benefit Corporation Law, this bill shall prevail.
Require CHHS to determine which department in the agency shall administer the foundation.
Create the Cancer Clinical Trials Fund within the State Treasury, appropriated by the Legislature to the board for the administration and support of the program.
Permit the Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
Permit CHHS to apply for federal funds.
Require the board to use no more than 20% of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
Limit spending for the establishment of the foundation to $300,000. Require startup funds used to establish the foundation be repaid with donations by 2021. Prohibit, after the initial investment, General Fund moneys from being used to operate the foundation.
Require, upon contribution of at least $500,000 to the foundation, the board to establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities.
Require the board to determine the criteria to award grants, and authorize grants to be awarded to either or both, public and private research institutions and hospitals that conduct cancer clinical trials approved by the federal Food and Drug Administration (FDA) and nonprofit organizations that specialize in direct patient support for improved clinical trial enrollment and retention, as specified.
Require grants to be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
Patient navigator services or programs;
Education and community outreach;
Patient-friendly technical tools to assist patients in identifying available clinical trials;
Translation and interpretation services of clinical trial information;
Counseling services for clinical trial participants;
Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management; and,
Payment of ancillary costs for patients and caregivers, including, but not limited to: airfare during the clinical trial, lodging during the clinical trial, rental cars during the clinical trial, fuel during the clinical trial, local transportation via bus, train, or other public transportation during the clinical trial, meals during the clinical trial, and child care costs during the clinical trial.
Specify repayment requirements if the foundation does not meet financial goals.
Require grant recipients to report to the board to ensure the appropriate use of funds within one year of receiving a grant.
Require the board to report to the Legislature specified data and recommendations by January 1, 2020. Makes the requirement for submitting a report inoperative on January, 1, 2024.
Sunset the provisions of this bill on January 1, 2022.
State legislative intent to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
EXISTING LAW:
Establishes the Inclusion of Women and Minorities in Clinical Research Act, which requires a grantee, defined, as any qualified public, private, or nonprofit agency or individual, including, but not limited to, colleges, universities, hospitals, laboratories, research institutions, local health departments, voluntary health agencies, health maintenance organizations, corporations, students, fellows, entrepreneurs, and individuals conducting clinical research using state funds, in conducting or supporting a project of clinical research, as defined, to ensure that women of all ages, and members of minority groups, as defined, are included as subjects in the clinical research projects, except under prescribed circumstances.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an FDA-approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician, recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
FISCAL EFFECT: According to the Senate Appropriations Committee, one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund). Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
COMMENTS:
Purpose of the Bill. The author states that this bill would increase participation of underrepresented communities in FDA approved clinical trials by creating a privately funded state grant program to help patients pay for the ancillary cost associated with participation in these trials. Studies show that there are a disproportionately low number of patients from minority communities in clinical trials of new drugs and cancer therapies. According to the author, one of the top reasons that patients report not participating in clinical trials is economic hardship. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. Clinical trials do not pay these ancillary costs. The costs fall onto the clinical trial participant who may be unable to pay and therefore, unable to enroll in the trial. The author contends that this bill creates an opportunity for the state to leverage public-private partnerships to improve the health and wellbeing of its residents with limited state investment.
Background. According to the Intercultural Cancer Center, only about 3 to 5% of the 10.1 million adults with cancer in the United States (U.S.) participate in cancer clinical trials. Clinical trials are a critical step in the discovery of new prevention, diagnostic, and treatment methods for cancer. Racial and ethnic minorities, older adults, rural residents, and individuals of low socioeconomic status are underrepresented among participants in cancer-related trials. Without adequate representation of these populations in clinical trials, researchers cannot learn about potential difference among groups and cannot ensure the generalization of results. In addition, participation in clinical trials increases access to state-of-the-art cancer care, a critical survival factor in many minorities and underrepresent populations that suffer disproportionately from cancer.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3-5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. The National Cancer Institute is the largest sponsor of cancer clinical trials at 3,000 sites. Over 30,000 patients are enrolled in cancer clinical trials annually. A review of FDA approved drugs from 1995-1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the SELECT prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities.
Barriers To Trial Participation. The Coalition to Eliminate Disparities and to Research Inclusion in Clinical Trials (CEDRICT) identified minority lack of disease education as a major barrier to recruitment. There are many different factors that have been attributed, in part, to the very low participation rate of all eligible patients in clinical trials, and the disproportionately low participation rate of minority populations. They include, among many other things:
Lack of awareness: A national survey of cancer patients found that 85% of respondents were unaware that participating in a clinical trial was a treatment option for them.
Language/Linguistic differences: Many U.S. clinical trials require English proficiency for potential participants, automatically excluding those who do not speak the language. Language factors also pose a serious barrier to provider-patient communications and attempts to recruit patients into clinical trials.
Mistrust: According to a review conducted by the Agency for Healthcare Research and Quality and others mistrust of research and the medical system is a frequently reported barrier to participating in clinical trials.
Practical obstacles: Transportation to and from a trial, particularly if it is located in a distant location, can be a barrier for many patients. Individuals with low incomes may find it difficult to take time off from work, find childcare or manage other family responsibilities while participating in a trial.
Public misconception: Among patients that are aware of clinical trials, a large percentage choose not to enroll, often due to a fear of getting a placebo in place of actual treatment, belief that standard treatment is better than what they would be offered in a clinical trial and fear of being a "guinea pig." In fact, placebos are rarely used in cancer treatment trials, and never in lieu of standard treatment.
Physician lack of awareness: Being unaware that clinical trials are available is one of the most common reasons physicians fail to refer patients to trials. Primary care physicians do not have sufficient information on available clinical trials, and often leave the discussion of clinical research to the patient's oncologist. Yet, many oncologists outside of the academic setting may also not be aware of trials or otherwise choose not to participate in or refer their eligible patients to clinical trials.
Federal Efforts To Increase Women And Minority Participation. The FDA Office of Women's Health (OWH) was established by congressional mandate to advocate for the participation of women in clinical trials and the analyses of data by sex. OWH supports studies to track the participation of women in clinical trials and collaborates with FDA centers and external partners to understand sex and gender differences in disease prevalence and response to therapy through science and research. The FDA Office of Minority Health is housed within the Office of the Commissioner and is the principal advisor on minority health and health disparities. The office is responsible for coordinating efforts throughout the FDA and has focused its efforts on three key areas: communicating and disseminating agency information to vulnerable populations; increasing participation of diverse health professionals in FDA activities to strengthen its capacity to address health disparities; and advocating for meaningful participation of minorities in clinical trials as well as the analysis of subpopulation data.
According to a 2011 report titled "Successful Strategies for Engaging Women and Minorities in Clinical Trials", NIH funded studies have specific diversity requirements, but aside from FDA recommendations, there are no regulations currently in place that require industry sponsors to include women and minorities in their trials. Diversity is not a natural priority for industry, where decisions often are made by market attractiveness and potential profit.
This bill was substantially amended in the Senate and the Assembly-approved provisions of this bill were deleted. This bill, as amended in the Senate is inconsistent with Assembly actions.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN: 0001888
AB 1060
Page 6
|
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 |
THIRD READING
Bill No: AB 1060
Amended: 8/31/15 in Senate
SENATE HEALTH COMMITTEE: 9-0, 7/15/15
AYES: Hernandez, Nguyen, Hall, Mitchell, Monning, Nielsen, Pan, Roth, Wolk
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/27/15
AYES: Lara, Bates, Beall, Hill, Leyva, Mendoza, Nielsen
ASSEMBLY FLOOR: 77-0, 5/7/15 (Consent) - See last page for vote
SUBJECT: Cancer clinical trials
SOURCE: Lazarex Cancer Foundation
DIGEST: This bill requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
Existing law:
Establishes the Inclusion of Women and Minorities in Clinical Research Act, which requires a grantee, defined, as any qualified public, private, or nonprofit agency or individual, including, but not limited to, colleges, universities, hospitals, laboratories, research institutions, local health departments, voluntary health agencies, health maintenance organizations, corporations, students, fellows, entrepreneurs, and individuals conducting clinical research using state funds, in conducting or supporting a project of clinical research, as defined, to ensure that women of all ages, and members of minority groups, as defined, are included as subjects in the clinical research projects, except under prescribed circumstances.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an U.S. Food and Drug Administration (FDA) approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
This bill:
Requires the California Health and Human Services Agency (CHHS) to establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, governed by a five-member board, appointed by the Governor, the Speaker of the Assembly, and the Pro Tempore of the Senate with a four-year term.
Creates the Cancer Clinical Trials Fund for the administration and support of the program. Requires moneys in the fund to be appropriated by the Legislature.
Permits the Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program. Permits applications for federal funds.
Requires the board to use no more than 20% of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
Limits CHHS from spending more than $300,000 to establish the foundation and requires the foundation to pay the funds back on or before January 1, 2021. Prohibits General Fund moneys to be used to operate the foundation.
Requires, upon contribution of at least $500,000, to the foundation, the board to establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities.
Requires the board to determine the criteria to award grants, and authorize grants to be awarded to either or both, public and private research institutions and hospitals that conduct cancer clinical trials approved by the FDA and nonprofit organizations that specialize in direct patient support for improved clinical trial enrollment and retention, as specified.
Requires the board to report to the Legislature to ensure the appropriate use of the funds. Requires the report to include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program, and to be submitted by January 1, 2020.
Requires the foundation to return moneys to the donors on a pro rata basis, after the repayment required in 3) above, if the foundation does not receive $500,000 or more by January 1, 2021. Sunsets this bill on January 1, 2022.
Comments
Author’s statement. According to the author, access to clinical trials is an important part of our health care system. It allows people to try innovative, alternative treatments when traditional treatments have not been successful and helps to get these new treatments approved for mainstream use. Unfortunately, we have seen limited access to clinical trials for women and people of color. One of the top reasons that patients report not participating in clinical trials is economic hardship. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. In addition, there are other barriers to trials such as lack of education and awareness of available cancer clinical trials. AB 1060 takes a step to increase access to cancer clinical trials by creating a privately funded grant program to connect patients with the appropriate clinical trial.
Clinical Trial Patient Challenges. According to a 2010 Workshop Summary of Transforming Clinical Research in the United States, many workshop participants noted that patients often are unaware of the possibility of enrolling in a clinical trial. If they are aware of this opportunity, it is often difficult for them to locate a trial. Patients may reside far from study centers; even the largest multicenter trials can pose geographic challenges for those wishing to participate. Depending on the number of clinic visits required by the study protocol, significant travel and time costs may be associated with participation. In addition, trials designed with narrow eligibility criteria for participation purposely eliminate many patients who might have the disease being studied but are ineligible because of other characteristics (e.g., age, level of disease progression, exposure to certain medicines). Trials often require patients to temporarily leave the care of their regular doctor and receive services from unfamiliar providers, confronting interruptions in care. If a patient reaches the point of enrolling in a clinical trial, the extensive paperwork associated with the informed consent process can be confusing and burdensome. Informed consent forms are developed to meet legal requirements and can contribute to the confusion patients feel regarding the trial and what it entails. In addition, there is sometimes a mistrust of industry-sponsored trials among the public. These feelings of mistrust can further complicate the already difficult decision about whether to join a trial.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3-5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. A review of FDA approved drugs from 1995-1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the SELECT prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities. With regard to challenges, the Fact Sheet indicates that 85% of respondents to a national survey were unaware that participating in a clinical trial was a treatment option for them. According to a review of enrollment decisions for health research studies, racial and ethnic minorities were less likely to be invited to participate in research studies compared with non-Hispanic/Latino whites.
FISCAL EFFECT: Appropriation: Yes Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
Anticipated one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund).
Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
Lazarex Cancer Foundation (source)
Association of Northern California Oncologists
Biocom
California Life Sciences Association
Pharmaceutical Researchers and Manufacturers of America
Stanford Healthcare
University of Southern California
OPPOSITION: (Verified 8/28/15)
None received
ARGUMENTS IN SUPPORT: According to the Lazarex Cancer Foundation this bill seeks to remedy the problem of low patient participation in clinical trials, especially participation by women and underrepresented communities. Lazarex states that the American Medical Association conducted a study on cancer trial participation and found from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1% were Hispanic, 9.2% were black, and 1.9% were Asian/Pacific Islanders, while 85.6% were white. The lack of diversity impacts researcher’s ability to evaluate the effect of new treatments on different populations, and speaks to a lack of access to potentially lifesaving trials for a large portion of the populations. The Association of Northern California Oncologists Board of Directors writes that clinical trials are an essential component of developing new and innovative treatments for all types of cancer and give vulnerable patients access to new treatment options that would not otherwise be available to them. This new foundation could raise funds to overcome barriers, helping the entire research process. The University of Southern California writes that this bill is an innovative approach focused on addressing barriers to patient participation in clinical trials. Biocom writes that although many companies operating in this space already have established programs to address this issue of clinical trial participation in underrepresented communities, it is hoped that a concerted state effort may reach trial candidates and their physicians more effectively.
ASSEMBLY FLOOR: 77-0, 5/7/15
AYES: Achadjian, Alejo, Travis Allen, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Holden, Irwin, Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Perea, Quirk, Rendon, Ridley-Thomas, Rodriguez, Salas, Santiago, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Atkins
NO VOTE RECORDED: Campos, Roger Hernández, Steinorth
Prepared by: Teri Boughton / HEALTH /
8/31/15 12:47:53
**** END ****
AB 1060
Page 6
|
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 |
THIRD READING
Bill No: AB 1060
Amended: 8/31/15 in Senate
SENATE HEALTH COMMITTEE: 9-0, 7/15/15
AYES: Hernandez, Nguyen, Hall, Mitchell, Monning, Nielsen, Pan, Roth, Wolk
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/27/15
AYES: Lara, Bates, Beall, Hill, Leyva, Mendoza, Nielsen
ASSEMBLY FLOOR: 77-0, 5/7/15 (Consent) - See last page for vote
SUBJECT: Cancer clinical trials
SOURCE: Lazarex Cancer Foundation
DIGEST: This bill requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
Existing law:
Establishes the Inclusion of Women and Minorities in Clinical Research Act, which requires a grantee, defined, as any qualified public, private, or nonprofit agency or individual, including, but not limited to, colleges, universities, hospitals, laboratories, research institutions, local health departments, voluntary health agencies, health maintenance organizations, corporations, students, fellows, entrepreneurs, and individuals conducting clinical research using state funds, in conducting or supporting a project of clinical research, as defined, to ensure that women of all ages, and members of minority groups, as defined, are included as subjects in the clinical research projects, except under prescribed circumstances.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an U.S. Food and Drug Administration (FDA) approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
This bill:
Requires the California Health and Human Services Agency (CHHS) to establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, governed by a five-member board, appointed by the Governor, the Speaker of the Assembly, and the Pro Tempore of the Senate with a four-year term.
Creates the Cancer Clinical Trials Fund for the administration and support of the program. Requires moneys in the fund to be appropriated by the Legislature.
Permits the Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program. Permits applications for federal funds.
Requires the board to use no more than 20% of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
Limits CHHS from spending more than $300,000 to establish the foundation and requires the foundation to pay the funds back on or before January 1, 2021. Prohibits General Fund moneys to be used to operate the foundation.
Requires, upon contribution of at least $500,000, to the foundation, the board to establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities.
Requires the board to determine the criteria to award grants, and authorize grants to be awarded to either or both, public and private research institutions and hospitals that conduct cancer clinical trials approved by the FDA and nonprofit organizations that specialize in direct patient support for improved clinical trial enrollment and retention, as specified.
Requires the board to report to the Legislature to ensure the appropriate use of the funds. Requires the report to include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program, and to be submitted by January 1, 2020.
Requires the foundation to return moneys to the donors on a pro rata basis, after the repayment required in 3) above, if the foundation does not receive $500,000 or more by January 1, 2021. Sunsets this bill on January 1, 2022.
Comments
Author’s statement. According to the author, access to clinical trials is an important part of our health care system. It allows people to try innovative, alternative treatments when traditional treatments have not been successful and helps to get these new treatments approved for mainstream use. Unfortunately, we have seen limited access to clinical trials for women and people of color. One of the top reasons that patients report not participating in clinical trials is economic hardship. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. In addition, there are other barriers to trials such as lack of education and awareness of available cancer clinical trials. AB 1060 takes a step to increase access to cancer clinical trials by creating a privately funded grant program to connect patients with the appropriate clinical trial.
Clinical Trial Patient Challenges. According to a 2010 Workshop Summary of Transforming Clinical Research in the United States, many workshop participants noted that patients often are unaware of the possibility of enrolling in a clinical trial. If they are aware of this opportunity, it is often difficult for them to locate a trial. Patients may reside far from study centers; even the largest multicenter trials can pose geographic challenges for those wishing to participate. Depending on the number of clinic visits required by the study protocol, significant travel and time costs may be associated with participation. In addition, trials designed with narrow eligibility criteria for participation purposely eliminate many patients who might have the disease being studied but are ineligible because of other characteristics (e.g., age, level of disease progression, exposure to certain medicines). Trials often require patients to temporarily leave the care of their regular doctor and receive services from unfamiliar providers, confronting interruptions in care. If a patient reaches the point of enrolling in a clinical trial, the extensive paperwork associated with the informed consent process can be confusing and burdensome. Informed consent forms are developed to meet legal requirements and can contribute to the confusion patients feel regarding the trial and what it entails. In addition, there is sometimes a mistrust of industry-sponsored trials among the public. These feelings of mistrust can further complicate the already difficult decision about whether to join a trial.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3-5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. A review of FDA approved drugs from 1995-1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the SELECT prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities. With regard to challenges, the Fact Sheet indicates that 85% of respondents to a national survey were unaware that participating in a clinical trial was a treatment option for them. According to a review of enrollment decisions for health research studies, racial and ethnic minorities were less likely to be invited to participate in research studies compared with non-Hispanic/Latino whites.
FISCAL EFFECT: Appropriation: Yes Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
Anticipated one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund).
Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
Lazarex Cancer Foundation (source)
Association of Northern California Oncologists
Biocom
California Life Sciences Association
City of Hope National Medical Center
Pharmaceutical Researchers and Manufacturers of America
Stanford Healthcare
University of Southern California
OPPOSITION: (Verified 8/28/15)
None received
ARGUMENTS IN SUPPORT: According to the Lazarex Cancer Foundation this bill seeks to remedy the problem of low patient participation in clinical trials, especially participation by women and underrepresented communities. Lazarex states that the American Medical Association conducted a study on cancer trial participation and found from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1% were Hispanic, 9.2% were black, and 1.9% were Asian/Pacific Islanders, while 85.6% were white. The lack of diversity impacts researcher’s ability to evaluate the effect of new treatments on different populations, and speaks to a lack of access to potentially lifesaving trials for a large portion of the populations. The Association of Northern California Oncologists Board of Directors writes that clinical trials are an essential component of developing new and innovative treatments for all types of cancer and give vulnerable patients access to new treatment options that would not otherwise be available to them. This new foundation could raise funds to overcome barriers, helping the entire research process. The University of Southern California writes that this bill is an innovative approach focused on addressing barriers to patient participation in clinical trials. Biocom writes that although many companies operating in this space already have established programs to address this issue of clinical trial participation in underrepresented communities, it is hoped that a concerted state effort may reach trial candidates and their physicians more effectively.
ASSEMBLY FLOOR: 77-0, 5/7/15
AYES: Achadjian, Alejo, Travis Allen, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Holden, Irwin, Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Perea, Quirk, Rendon, Ridley-Thomas, Rodriguez, Salas, Santiago, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Atkins
NO VOTE RECORDED: Campos, Roger Hernández, Steinorth
Prepared by: Teri Boughton / HEALTH /
8/31/15 19:58:29
**** END ****
AB 1060 (Bonilla) Page 0 of 1
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
AB 1060 (Bonilla) - Cancer clinical trials
|
|
Version: July 16, 2015 |
Policy Vote: HEALTH 9 - 0 |
Urgency: No |
Mandate: No |
Hearing Date: August 27, 2015 |
Consultant: Brendan McCarthy |
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 27, 2015
Bill Summary:
AB 1060 would require the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation, to increase patient access to clinical trials.
Fiscal Impact:
Anticipated one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund).
Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
Author Amendments:
Delete the continuous appropriation, limit spending for the establishment of the foundation to $300,000, require startup funds to be repaid with donations by 2021, prohibit the use of General Fund money for ongoing costs, specify that the grant program will begin once $500,000 in donations has been received, specify repayment requirements if the foundation does not meet financial goals, and sunset the program in 2022.
-- END --
AB 1060 (Bonilla) Page 2 of 2
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
AB 1060 (Bonilla) - Cancer clinical trials
|
|
Version: July 16, 2015 |
Policy Vote: HEALTH 9 - 0 |
Urgency: No |
Mandate: No |
Hearing Date: August 17, 2015 |
Consultant: Brendan McCarthy |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
AB 1060 would require the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation, to increase patient access to clinical trials.
Fiscal Impact:
Anticipated one-time costs of $650,000 to establish the nonprofit foundation, develop grant guidelines, provide initial administrative support to the foundation, and begin the initial fundraising effort before sufficient donations have been received to support the foundation (General Fund).
Unknown annual costs to award grants and provide administrative support to the new foundation (private funds). The amount of grant funding that the foundation will be able to award will depend on future donations from the public as will the level of administrative support needed to award the grants and manage the foundation.
Background:
Clinical trials are conducted by pharmaceutical companies seeking approval to market new drugs or existing drugs for additional conditions. In addition, the federal government provides financial support for clinical trials designed to study medical effectiveness or other characteristics of new or existing drugs.
In recent years, concerns have been raised that participants in clinical trials tend not to reflect the larger society, which may bias the results of those trials. Research findings indicate that participants in clinical trials are more likely to be male and to be Caucasian than the general population. Clinical trials tend to be conducted at academic medical centers, often require patients to receive their care from a new doctor participating in the trial and often require substantial paperwork for patients to enroll. These factors and others have tended to limit participation in clinical trials.
Proposed Law:
AB 1060 would require the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation, to increase patient access to clinical trials.
Specific provisions of the bill would:
Require the Agency to establish the Cancer Clinical Trials Foundation as a nonprofit public benefit corporation, with an appointed board;
Specify the process for appointing board members;
Require the Agency to determine which department within the agency shall administer the foundation;
Establish a new special fund to support the foundation and continuously appropriate monies in that fund;
Authorize the Foundation to solicit donations from public and private sources;
Limit administrative costs to 20% of total program expenditures;
Require the Foundation board to establish a grant program, upon receipt of an unspecified amount of donations;
Authorize grants to be made to research institutions and hospitals and to nonprofit organizations that specialize in patient support for clinical trial participation;
Specify the allowed uses of the grant funds, including a variety of services and reimbursement of patient costs all intended to support patient participation in clinical trials;
Require the Foundation to report to the Legislature on its activities by January 1, 2020.
Staff Comments:
The intent of the bill is for the Foundation to be supported by public and private donations, rather than the General Fund. However, the Agency or a delegated department would incur initial costs to establish the Foundation as a nonprofit before any donations could be received.
Staff recommends that the bill be amended to ensure that any startup costs incurred by a state department be reimbursed by initial donations to the foundation. Staff recommends that the continuous appropriation be removed from the bill to allow for Legislative oversight of the Foundation. Also, staff recommends that an appropriate sunset date be added to the bill, to ensure that the state does not continue to provide administrative support indefinitely if future donations do not materialize.
-- END --
AB 1060 (Bonilla) Page 5 of 5
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: AB 1060
AUTHOR: |
Bonilla |
||
VERSION: |
June 17, 2015 |
||
HEARING DATE: |
July 15, 2015 |
|
|
CONSULTANT: |
Teri Boughton |
||
SUBJECT: Cancer clinical trials.
SUMMARY:
Requires the California Health and Human Services Agency to establish a nonprofit Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
Existing law:
Establishes the Inclusion of Women and Minorities in Clinical Research Act, which requires a grantee, defined, as any qualified public, private, or nonprofit agency or individual, including, but not limited to, colleges, universities, hospitals, laboratories, research institutions, local health departments, voluntary health agencies, health maintenance organizations, corporations, students, fellows, entrepreneurs, and individuals conducting clinical research using state funds, in conducting or supporting a project of clinical research, as defined, to ensure that women of all ages, and members of minority groups, as defined, are included as subjects in the clinical research projects, except under prescribed circumstances.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an U.S. Food and Drug Administration (FDA) approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
This bill:
Requires the California Health and Human Services Agency (CHHS) to establish a nonprofit public benefit corporation, to be known as the Cancer Clinical Trials Foundation, governed by a five member board, appointed by the Governor, the Speaker of the Assembly, and the Pro Tem of the Senate with a four year term.
Requires the Governor to appoint the president of the board and requires members of the board to serve without compensation but reimbursed for any actual and necessary expenses incurred in connection with their duties as members of the board.
Subjects the foundation to the Nonprofit Public Benefit Corporation Law, as specified, except that if there is a conflict with this bill and the Nonprofit Public Benefit Corporation Law, this bill shall prevail.
Requires CHHS to determine which department in the agency shall administer the foundation.
Creates the Cancer Clinical Trials Fund, continuously appropriated to the board without regard to fiscal years, for the administration and support of the program.
Permits the Cancer Clinical Trials Foundation to solicit and receive funds from business, industry, foundations, and other private and public sources for the purpose of administering the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials.
Requires the board to use no more than 20% of funds made available for the Cancer Clinical Trials Grant Program for administrative costs.
Requires, upon contribution of an unspecified amount of moneys to the foundation, the board to establish the Cancer Clinical Trials Grant Program to increase patient access to cancer clinical trials in underserved or disadvantaged communities and populations, including among women and patients from racial and ethnic minority communities.
Requires the board to determine the criteria to award grants, and authorize grants to be awarded to either or both, public and private research institutions and hospitals that conduct cancer clinical trials approved by the FDA and nonprofit organizations that specialize in direct patient support for improved clinical trial enrollment and retention, as specified.
Requires grants to be used for activities to increase patient access to cancer clinical trials, including, but not limited to, any of the following:
Patient navigator services or programs;
Education and community outreach;
Patient-friendly technical tools to assist patients in identifying available clinical trials;
Translation and interpretation services of clinical trial information;
Counseling services for clinical trial participants;
Well-being services for clinical trial participants, including, but not limited to, physical therapy, pain management, stress management, and nutrition management; and,
Payment of ancillary costs for patients and caregivers, including, but not limited to: airfare during the clinical trial, lodging during the clinical trial, rental cars during the clinical trial, fuel during the clinical trial, local transportation via bus, train, or other public transportation during the clinical trial, meals during the clinical trial, and child care costs during the clinical trial.
Requires grant recipients to report to the board to ensure the appropriate use of funds within one year of receiving a grant.
Requires the board to report to the Legislature to ensure the appropriate use of the funds. Requires the report to include accountability measures, including, but not limited to, a description of how the funds were used, an evaluation of the grant program, and recommendations for the program, and to be submitted by January 1, 2020.
Makes the requirement for submitting a report imposed under this bill inoperative on January, 1, 2024, as specified.
States legislative intent to establish a program to enable willing patients of low to moderate income to participate in cancer clinical trials in order to boost participation rates, ensure these trials are widely accessible, improve the development of cancer therapies, and enhance innovation.
FISCAL EFFECT:
This version of the bill has not been analyzed by a fiscal committee.
PRIOR VOTES:
The prior votes are not relevant to this version of the bill.
COMMENTS:
Author’s statement. According to the author, access to clinical trials is an important part of our health care system. It allows people to try innovative, alternative treatments when traditional treatments have not been successful and helps to get these new treatments approved for mainstream use. Unfortunately, we have seen limited access to clinical trials for women and people of color. One of the top reasons that patients report not participating in clinical trials is economic hardship. There are many costs associated with participating in a clinical trial including transportation costs, hotel costs, and companion traveling expenses. In addition, there are other barriers to trials such as lack of education and awareness of available cancer clinical trials. AB 1060 takes a step to increase access to cancer clinical trials by creating a privately funded grant program to connect patients with the appropriate clinical trial.
Clinical Trial Challenges. A 2010 Workshop Summary of Transforming Clinical Research in the United States (Summary) provides some background into the clinical trial process. According to the summary, because clinical trials are necessary to obtain regulatory approval in the United States, they are a high priority to companies. Industry-sponsored trials are conducted largely to gain FDA approval to market a new drug or a previously approved drug for a new indication. Pre-approval trials include a simple protocol (i.e., ask a limited number of questions) and test a drug in a highly selected patient group designed to provide the most robust evidence on the drug’s benefits and risks. Conversely, the federal government conducts large clinical trials to answer medical questions unrelated to gaining regulatory approval for a new drug or therapy. These studies can involve a wide range of patients and seek to answer a number of relevant clinical questions at once.
Clinical
trial costs can vary widely depending on the number of patients being
sought, the number and location of research sites, the complexity of
the trial protocol, and the reimbursement provided to investigators.
The total cost can reach $300–$600 million to implement, conduct,
and monitor a large, multicenter trial to completion.
The
Summary includes a discussion about patient challenges. According to
the summary, many workshop participants noted that patients often are
unaware of the possibility of enrolling in a clinical trial. If they
are aware of this opportunity, it is often difficult for them to
locate a trial. Patients may reside far from study centers; even the
largest multicenter trials can pose geographic challenges for those
wishing to participate. Depending on the number of clinic visits
required by the study protocol, significant travel and time costs may
be associated with participation. In addition, trials designed with
narrow eligibility criteria for participation purposely eliminate
many patients who might have the disease being studied but are
ineligible because of other characteristics (e.g., age, level of
disease progression, exposure to certain medicines). Trials often
require patients to temporarily leave the care of their regular
doctor and receive services from unfamiliar providers, confronting
interruptions in care. If
a patient reaches the point of enrolling in a clinical trial, the
extensive paperwork associated with the informed consent process can
be confusing and burdensome. Informed consent forms are developed to
meet legal requirements and can contribute to the confusion patients
feel regarding the trial and what it entails.
In addition, there is sometimes a mistrust of industry-sponsored
trials among the public. These feelings of mistrust can further
complicate the already difficult decision about whether to join a
trial.
Disparities. A Cancer Clinical Trial Fact Sheet made possible by an unrestricted educational grant from Genentech, provided by the author, indicates that only about 3-5% of the 10.1 million adults with cancer in the U.S. participate in cancer trials. This compares to 60% participation rate for children with cancer. The National Cancer Institute is the largest sponsor of cancer clinical trials at 3,000 sites. Over 30,000 patients are enrolled in cancer clinical trials annually. A review of FDA approved drugs from 1995-1999 revealed that African Americans, Asian/Pacific Islanders, Hispanics/Latinos and Native Americans collectively represented less than 10% of participants in trials that were testing cancer drugs. In 2004, the SELECT prostate cancer prevention trial completed recruiting over 35,000 men of whom 21% were minorities. With regard to challenges, the Fact Sheet indicates that 85% of respondents to a national survey were unaware that participating in a clinical trial was a treatment option for them. According to a review of enrollment decisions for health research studies, racial and ethnic minorities were less likely to be invited to participate in research studies compared with non-Hispanic/Latino whites.
Prior legislation. AB 2038 (Alquist Chapter 250, Statutes of 2000), establishes the Inclusion of Women and Minorities in Clinical Research Act.
Support. According to the Lazarex Cancer Foundation this bill seeks to remedy the problem of low patient participation in clinical trials, especially participation by women and underrepresented communities. The American Medical Association conducted a study on cancer trial participation and found from 1996 to 2002, of the 75,215 patients enrolled in the National Cancer Institute trials for breast, lung, colorectal, and prostate cancers, only 3.1% were Hispanic, 9.2% were black, and 1.9% were Asian/Pacific Islanders, while 85.6% were white. The lack of diversity impacts researcher’s ability to evaluate the effect of new treatments on different populations, and speaks to a lack of access to potentially lifesaving trials for a large portion of the populations. The Association of Northern California Oncologists Board of Directors writes that clinical trials are essential component of developing new and innovative treatments for all types of cancer and give vulnerable patients access to new treatment options that would not otherwise be available to them. This new foundation could raise funds to overcome barriers, helping the entire research process. The University of Southern California writes that this bill is an innovative approach focused on addressing barriers to patient participation in clinical trials. Biocom writes that although many companies operating in this space already have established programs to address this issue of clinical trial participation in underrepresented communities, it is hoped that a concerted state effort may reach trial candidates and their physicians more effectively.
Amendments. The author requests the adoption of amendments to direct the foundation, or an authorized representative thereof, to apply for tax exempt status under Section 501 (c)(3) of the Internal Revenue Code.
SUPPORT AND OPPOSITION:
Support: Lazarex Cancer Foundation (sponsor)
Association of Northern California Oncologists
Biocom
California Life Sciences Association
Pharmaceutical Researchers and Manufacturers of America
University of Southern California
Oppose: None received
-- END --
AB 1060
Page 2
Date of Hearing: April 29, 2015
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Jimmy Gomez, Chair
AB 1060
(Bonilla) – As Amended March 26, 2015
Policy Committee: |
Business and Professions |
Vote: |
14 - 0 |
|
|
|
|
|
|
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY: This bill clarifies that a board or bureau under the Department of Consumer Affairs (DCA) must provide specified information, when a license is suspended or revoked, to an ex-licensee by both first-class mail and by email if a board or bureau has an email address on file for the ex-licensee.
FISCAL EFFECT:
Costs will be minor and absorbable within existing DCA resources.
COMMENTS:
Purpose. According to the author, "The boards and bureaus within the DCA are given independent authority to suspend or revoke a license on the grounds that the licensee was convicted of a crime that is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. In the event of a license suspension or revocation, boards and bureaus are required to provide the ex-licensee with certain information regarding rehabilitation, reinstatement, or reduction of the penalty. Current law does not specify the means by which this notification is to be made. This bill clarifies that the required information must be sent by first-class mail and email, if an email address is on file with the board or bureau.
License Revocation and License Suspension. Each board and bureau has its own enforcement provisions and is responsible for determining if a license should be suspended or revoked. According to the DCA, there is no standard method by which a board or bureau implements its own suspension and revocation program. Depending on the board or bureau, a license revocation typically means that a license will not be reinstated or reissued for a period of one to five years from the effective date of the decision. A license suspension typically means that the licensee is not entitled to operate during the period of suspension.
According to the DCA, the number of suspensions and revocations vary based on each board or bureau's disciplinary scheme. In fiscal year (FY) 2013-14, the Board of Behavioral Sciences suspended one license and revoked 17, while in FY 2013-14, the Bureau of Real Estate suspended approximately 182 licensed and revoked approximately 649 licenses. Regardless of a suspension or revocation, or a board's disciplinary policies, if a license is suspended or revoked, a board is required to send information about the procedures and criteria for license rehabilitation. A board relies upon individuals to update their email and mailing addresses and does not always have updated contact information.
Prior Legislation. AB 1025 (Bass) of 2007, would have provided that an applicant may not be denied licensure, or may not have their license suspended or revoked, solely on the basis that he or she has been convicted of a felony or misdemeanor if they have obtained a certificate of rehabilitation. If the felony or misdemeanor conviction had been dismissed, it would have presumed that the applicant or licensee had been rehabilitated unless a board proved otherwise. That bill was vetoed by Governor Schwarzenegger.
Analysis Prepared by: Jennifer Swenson / APPR. / (916) 319-2081
AB 1060
Page 3
Date of Hearing: April 14, 2015
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Susan Bonilla, Chair
AB 1060
(Bonilla) – As Amended March 26, 2015
SUBJECT: MERGEFIELD bill \* MERGEFORMAT Professions and vocations: licensure.
SUMMARY: Clarifies that a board or bureau under the Department of Consumer Affairs (DCA) (hereafter referred to as "a board") must provide specified information, when a license is suspended or revoked, to an ex-licensee through first-class mail and by email if a board has an email address on file for the ex-licensee.
EXISTING LAW
Permits a board to deny a license, as specified. (Business and Professions Code (BPC) Section 480).
Permits a board to suspend or revoke a license on the grounds that the licensee has been convicted of a crime, if the crime is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. (BPC Section 490(a)).
Defines a “conviction,” as referenced above, to mean a plea or verdict of guilty or a conviction following a plea of nolo contendere and states that any action that a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, or the judgment of a conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order, as specified. (BPC Section 490(c)).
Permits a board to suspend a license as specified, if a licensee is not in compliance with a child support order. (BPC Section 490.5).
Requires a board, upon a suspension or revocation of a license on one or more of the grounds referenced in two above, to:
Send a copy of the provisions of Government Code Section 11522 regarding reinstatement or reduction of the penalty, as specified; and,
A copy of the criteria relating to rehabilitation, as specified. (BPC Section 491(a)(b)).
Requires a board, as specified, to develop criteria to evaluate the rehabilitation of a person when:
Considering the denial of a license; or,
Considering suspension or revocation of a license. (BPC Section 482(a)(b)).
Requires a board to take into account all competent evidence of rehabilitation furnished by the applicant or licensee. (BPC Section 482).
THIS BILL
Requires a board to send specified information to an ex-licensee by first class mail and email if a board has an email address on file for the ex-licensee.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by the Legislative Counsel.
COMMENTS
Purpose. This bill is author sponsored. According to the author, "Existing law provides for the licensure and regulation of various professions and vocations within the DCA. The boards and bureaus are given independent authority to suspend or revoke a license on the ground that the licensee was convicted of a crime that is substantially related to the qualifications, functions, or duties of the business or profession for which the license was issued. In the event of a license suspension or revocation, boards and bureaus are required to provide the ex-licensee with certain information regarding rehabilitation, reinstatement, or reduction of the penalty; however, current law does not specify the means by which this notification is to be made. This bill simply clarifies that the required information must be sent by first-class mail and email, if an email address is on file with the board or bureau. This will help create consistency amongst the boards and bureaus in distributing the information and will increase the likelihood that an ex-licensee receives this valuable information."
Background. This bill will clarify that a board who suspends, revokes, or denies a license is required to inform individuals about pertinent rehabilitation criteria and procedures. Currently, the boards and bureaus under the DCA are required to notify ex-licensees, however, the method of delivery is not specified and may be inconsistent.
In addition to the denial of an application for licensure, a board is permitted to suspend or revoke the license of an individual who has been convicted of a crime that is substantially related to the functions or duties of the business or profession for which the individual is licensed. Once a board has decided to suspend or revoke a license, a board is then required to send the ex-licensee, the individual whose license was revoked or suspended, certain information about the procedures and criteria for license rehabilitation. However, the law is not clear on the delivery method for this information to be sent to the ex-licensee.
This bill simply requires a board to send the rehabilitation criteria and relevant information by first-class mail and by email if a board has an email address on file for the ex-licensee. A board relies upon individuals to update their email and mailing addresses and does not always have updated contact information. By requiring a board to send this information via mail and electronic mail, it will help ensure that the ex-licensee receives the required material about rehabilitation criteria.
License Revocation and License Suspension. Each board has its own enforcement provisions and is responsible for determining if a license should be suspended or revoked. According to the DCA, there is no standard method by which a board implements its own suspension and revocation program. Depending on the board, a license revocation typically means that a license will not be reinstated or reissued for a period of one to five years from the effective date of the decision. A license suspension typically means that the licensee is not entitled to operate during the period of suspension. According to the DCA, the number of suspensions and revocations vary based on each board's disciplinary scheme. In fiscal year (FY) 2013-14, the Board of Behavioral Sciences suspended one license and revoked 17, while in FY 2013-14, the Bureau of Real Estate suspended approximately 182 licensed and revoked approximately 649 licenses. Regardless of a suspension or revocation, or a board's disciplinary policies, if a license is suspended or revoked, a board is required to send information about the procedures and criteria for license rehabilitation. This bill specifies that the information is to be sent by first-class mail and email, if the board has an email address on file for the ex-licensee.
Prior Related Legislation. AB 1025 (Bass) of 2007, would have provided that an applicant for a license with a board may not be denied licensure, or may not have their license suspended or revoked, solely on the basis that he or she has been convicted of a felony or misdemeanor if they have obtained a certificate of rehabilitation and if the felony or misdemeanor conviction has been dismissed, it shall be presumed that the applicant or licensee has been rehabilitated unless a board proves otherwise. NOTE: This bill was vetoed by Governor Schwarzenegger.
REGISTERED SUPPORT / OPPOSITION:
Support
None on file.
Opposition
None on file.
Analysis Prepared by: Elissa Silva / B. & P. / (916) 319-3301
Discussed in Hearing
Assembly Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):